Review the latest evidence-based strategies on individualized early breast cancer treatment with expert commentaries, online modules, downloadable slidesets, and an Interactive Decision Support Tool that provides personalized management recommendations for treatment selection in early breast cancer.
Resources for your patients: https://www.smartpatients.com/resources/cco-ebc
This module offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.
This module offers an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.
In this module, an expert reviews germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.
In this module, an expert reviews the latest evidence on immune checkpoint inhibition in the neoadjuvant and adjuvant settings in high-risk, early-stage triple-negative breast cancer.
This module offers a focused expert review of ongoing clinical trials most likely to inform management of patients with HR-positive/HER2-negative early-stage breast cancer.